Cargando…

Resistance to aztreonam-avibactam due to a mutation of SHV-12 in Enterobacter

Aztreonam-avibactam is an important option against Enterobacterales producing metallo-β-lactamases (MBLs). We obtained an aztreonam-avibactam-resistant mutant of an MBL-producing Enterobacter mori strain by induced mutagenesis. Genome sequencing revealed an Arg244Gly (Ambler position) substitution o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Shikai, Ma, Ke, Feng, Yu, Zong, Zhiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294450/ https://www.ncbi.nlm.nih.gov/pubmed/37365592 http://dx.doi.org/10.1186/s12941-023-00605-y

Ejemplares similares

Aztreonam-avibactam: an option against carbapenem-resistant Enterobacterales with emerging resistance
por: Wu, Shikai, et al.
Publicado: (2022)

Resistance to aztreonam-avibactam due to CTX-M-15 in the presence of penicillin-binding protein 3 with extra amino acids in Escherichia coli
por: Ma, Ke, et al.
Publicado: (2022)

Struggle To Survive: the Choir of Target Alteration, Hydrolyzing Enzyme, and Plasmid Expression as a Novel Aztreonam-Avibactam Resistance Mechanism
por: Ma, Ke, et al.
Publicado: (2020)

Successful treatment of infective endocarditis due to pandrug-resistant Klebsiella pneumoniae with ceftazidime-avibactam and aztreonam
por: Alghoribi, Majed F., et al.
Publicado: (2021)

In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China
por: Yu, Wei, et al.
Publicado: (2021)

Success of ceftazidime–avibactam and aztreonam in combination for a refractory biliary infection with recurrent bacteraemia due to blaIMP-4 carbapenemase-producing Enterobacter hormaechei subsp. oharae
por: McKew, Genevieve, et al.
Publicado: (2021)

In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria
por: Emeraud, Cécile, et al.
Publicado: (2023)

Antibacterial Activity and Optimal Treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae
por: Yu, Wei, et al.
Publicado: (2021)

Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro
por: Lin, Qiuxia, et al.
Publicado: (2021)

1422. Comparative Monte-Carlo Analysis of Aztreonam-Avibactam vs. Ceftazidime–Avibactam Against Carbapenem-Resistant Gram-Negative Pathogens
por: Smith, Aaron, et al.
Publicado: (2018)

In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant Enterobacterales Isolates from South Korea
por: Kim, Taeeun, et al.
Publicado: (2020)

Antibacterial potential of Forsythia suspensa polysaccharide against resistant Enterobacter cloacae with SHV‐12 extended‐spectrum β‐lactamase (ESBL)
por: Liu, Jun, et al.
Publicado: (2020)

In Vitro Activities of Ceftazidime–Avibactam and Aztreonam–Avibactam at Different Inoculum Sizes of Extended-Spectrum β-Lactam-Resistant Enterobacterales Blood Isolates
por: Bae, Moonsuk, et al.
Publicado: (2021)

CP-CRE/non-CP-CRE Stratification And CRE Resistance Mechanism Determination Help In Better Managing CRE Bacteremia Using Ceftazidime–Avibactam And Aztreonam–Avibactam
por: Zou, Hua, et al.
Publicado: (2019)

Carbapenem-Resistant Enterobacter hormaechei ST1103 with IMP-26 Carbapenemase and ESBL Gene bla(SHV-178)
por: Gou, Jian-Jun, et al.
Publicado: (2020)

Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China
por: Sun, Shan, et al.
Publicado: (2022)

2756. Activity of Aztreonam-avibactam and Ceftazidime-avibactam against United States Isolates Producing β-lactamases (2020–2021)
por: Castanheira, Mariana, et al.
Publicado: (2023)

Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales
por: Kelley, C. J., et al.
Publicado: (2022)

Characterization of ESBL (SHV-12) producing clinical isolate of Enterobacter aerogenes from a tertiary care hospital in Nigeria
por: Kasap, Murat, et al.
Publicado: (2010)

MBLs, Rather Than Efflux Pumps, Led to Carbapenem Resistance in Fosfomycin and Aztreonam/Avibactam Resistant Elizabethkingia anophelis
por: Chang, Yanbin, et al.
Publicado: (2021)

In vitro and in vivo Antimicrobial Activities of Ceftazidime/Avibactam Alone or in Combination with Aztreonam Against Carbapenem-Resistant Enterobacterales
por: Lu, Guoping, et al.
Publicado: (2022)

Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study
por: Krishnan, Nikhil P., et al.
Publicado: (2015)

1686. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients
por: Sader, Helio S, et al.
Publicado: (2022)

In Vitro Evaluation of the Activity of Aztreonam-Avibactam against 341 Recent Clinical Isolates of Anaerobes
por: Snydman, David R., et al.
Publicado: (2021)

Evaluation of Aztreonam and Ceftazidime/Avibactam Synergism against Klebsiella pneumoniae by MALDI-TOF MS
por: Wilhelm, Camila Mörschbächer, et al.
Publicado: (2023)

Epidemiology and Genomic Characteristics of Bloodstream Infection Caused by Carbapenem-Resistant Klebsiella pneumoniae With Decreased Susceptibility to Aztreonam/Avibactam in China
por: Yu, Wei, et al.
Publicado: (2022)

Detection of new SHV-12, SHV-5 and SHV-2a variants of extended spectrum Beta-lactamase in Klebsiella pneumoniae in Egypt
por: Newire, Enas A, et al.
Publicado: (2013)

Multidrug-resistant phenotype and isolation of a Novel SHV- beta-Lactamase variant in a clinical isolate of Enterobacter cloacae
por: Bourouis, Amel, et al.
Publicado: (2015)

2443. Searching for the Optimal Treatment Regimen for Metallo-β-Lactamase Producing Enterobacteriaceae: Aztreonam Plus Ceftazidime–Avibactam vs. Aztreonam Plus Meropenem–Vaborbactam
por: Biagi, Mark, et al.
Publicado: (2018)

In Vitro Activities and Inoculum Effects of Cefiderocol and Aztreonam-Avibactam against Metallo-β-Lactamase-Producing Enterobacteriaceae
por: Huang, Yu-Shan, et al.
Publicado: (2023)

Precise Species Identification for Enterobacter: a Genome Sequence-Based Study with Reporting of Two Novel Species, Enterobacter quasiroggenkampii sp. nov. and Enterobacter quasimori sp. nov.
por: Wu, Wenjing, et al.
Publicado: (2020)

2189. Colistin Heteroresistance in Enterobacter due to Base Heterozygosity at Certain phoPQ Locations
por: Wang, Chengcheng, et al.
Publicado: (2023)

In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019
por: Zou, Chunhong, et al.
Publicado: (2020)

In vitro activity of cefiderocol against comparators (ceftazidime-avibactam, ceftazidime-avibactam/ aztreonam combination, and colistin) against clinical isolates of meropenem-resistant Klebsiella pneumoniae from India
por: Borde, Kalyani, et al.
Publicado: (2023)

Ca-EDTA restores the activity of ceftazidime-avibactam or aztreonam against carbapenemase-producing Klebsiellapneumoniae infections
por: Wannigama, Dhammika Leshan, et al.
Publicado: (2023)

1607. Dual Therapy with Aztreonam & Ceftazidime/Avibactam Against Multi-Drug Resistant Stenotrophomonas maltophilia on Tricuspid Valve Endocarditis
por: Alexander, Jose, et al.
Publicado: (2020)

Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms
por: Khan, Ayesha, et al.
Publicado: (2021)

Ceftazidime-avibactam with or without Aztreonam vs Polymyxin-based Combination Therapy for Carbapenem-resistant Enterobacteriaceae: A Retrospective Analysis
por: Prayag¹, Parikshit S, et al.
Publicado: (2023)

Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa
por: Kang, Yixin, et al.
Publicado: (2023)

2146. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-avibactam, and Meropenem-vaborbactam against Enterobacterales causing Bloodstream Infection in US Medical Centers (2020–2022)
por: Sader, Helio S, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p0mjqka12tpd9g5p3jj8qe6vas